Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Operationally Seamless Phase II / III Study of 131I-apamistamab-Led Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia With Active Disease

NCT07157514 is registered in ClinicalTrials.gov with Actinium Pharmaceuticals as lead sponsor.

NCT NCT07157514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07157514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Operationally Seamless Phase II / III Study of 131I-apamistamab-Led Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia With Active Disease
Lead sponsor
Actinium Pharmaceuticals
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
February 28, 2034
Enrollment
306 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute myelogenous leukemia, acute myeloid leukemia, acute myeloid leukemia, in relapse, allogeneic disease, myelogenous leukemia, myelogenous leukemia in relapse, myelogenous leukemia, acute, myeloid leukemia, refractory aml, transplant-related disorder